Regulatory T cell as a restorative therapy for ischemic stroke

调节性 T 细胞作为缺血性中风的恢复疗法

基本信息

  • 批准号:
    9619010
  • 负责人:
  • 金额:
    $ 33.69万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-03-15 至 2022-07-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): White matter (WM) lesions, characterized by the loss of myelin and myelin-producing oligodendrocytes (OLs), are a major cause of functional disability after stroke but have not been widely appreciated in therapeutic studies until recently. Here we propose to rectify this gap in the field by focusing on WM integrity and its modulation by immune responses in the ischemic brain. Activated microglia/macrophages of distinct phenotypes are known to determine OL cell fate and WM integrity after brain injuries. Specifically, the "alternatively activated" M2 phenotype is essential for WM preservation and repair because M2 cells resolve local inflammation, clear broken myelin sheaths, and provide trophic factors that promote WM repair. CD4+CD25+ regulatory T cells (Tregs) are a specialized subpopulation of T cells that negatively regulate immune responses. Our recent study demonstrated that adoptive Treg therapy exerted early neuroprotection by targeting inflammatory dysregulation and neurovascular disruption after stroke. However, it is not known whether Tregs also have a beneficial effect on WM integrity. Recently, we discovered that Treg-conditioned media stimulates microglial polarization toward the M2 phenotype, and M2 microglia enhance OL survival and promote OPC differentiation in vitro. These exciting results suggest that Tregs can preserve WM integrity. We obtained further promising data showing that 1) Treg transfer at 2h of reperfusion reduced the extent of WM injury and improved sensorimotor functions for at least 28d after transient middle cerebral artery occlusion (tMCAO); 2) Post-stroke Treg treatment resulted in a long-lasting elevation of IL-10, a major Treg-derived cytokine that is important for WM repair; 3) Treg treatment promoted M2 polarization of microglia/macrophages in both WM and gray matter after tMCAO. Furthermore, we have successfully induced a robust increase of Tregs in the circulation after stroke by systemic injection of interleukin (IL)-2/IL-2 antibody complex (IL-2/IL- 2Ab), an established approach to expand Tregs in vivo. We demonstrated that IL-2/IL-2Ab-induced Treg expansion reduces myelin loss 7d after tMCAO and improves sensorimotor functions. The current proposal will further explore the effects of Tregs on WM injury and repair after stroke and develop in vivo Treg expansion as a novel strategy to promote WM integrity and enhance post-stroke recovery. The central hypothesis to be tested is that Tregs promote WM integrity and long-term recovery after stroke by polarizing microglia/macrophages toward the M2 phenotype in an IL-10 dependent manner. Three specific aims are proposed: Aim 1. Test the hypothesis that Treg treatment after stroke improves long-term functional recovery and promotes WM integrity. Aim 2. Test the hypothesis that Treg-derived IL-10 shifts microglia/macrophage polarization towards the M2 phenotype, thereby promoting WM integrity after stroke. Aim 3. Test the hypothesis that in vivo expansion of Tregs with post-stroke IL-2/IL-2Ab treatment is effective in reducing long-term WM injury and improving neurological recovery after stroke.
 描述(申请人提供):白质(WM)损害,其特征是髓鞘丢失和产生髓鞘的少突胶质细胞(OLs),是中风后功能障碍的主要原因,但直到最近才在治疗研究中被广泛认识。 在这里,我们建议通过关注WM的完整性及其在缺血脑中的免疫反应调节来纠正这一领域的差距。不同表型的激活的小胶质细胞/巨噬细胞决定了脑损伤后OL细胞的命运和WM的完整性。具体地说,“交替激活”的M2表型对于WM的保存和修复是必不可少的,因为M2细胞可以解决局部炎症,清除破碎的髓鞘,并提供促进WM修复的营养因子。CD4+CD25+调节性T细胞(Tregs)是一种特殊的T细胞亚群,对免疫反应具有负性调节作用。我们最近的研究表明,过继Treg疗法通过靶向卒中后炎性调节障碍和神经血管破坏而发挥早期神经保护作用。然而,目前还不知道Tregs是否也对WM的完整性有有益的影响。最近,我们发现Treg条件培养液刺激小胶质细胞向M2表型分化,M2小胶质细胞在体外提高了OL的存活率和促进OPC的分化。这些令人兴奋的结果表明,Tregs可以保持WM的完整性。我们获得了进一步的有希望的数据:1)再灌注2小时的Treg转移减少了WM的损伤程度,并至少在28d内改善了感觉运动功能;2)卒中后Treg治疗导致IL-10持续升高,IL-10是一种对WM修复至关重要的Treg衍生细胞因子;3)Treg治疗促进了tMCAO后西区和灰质中小胶质细胞/巨噬细胞的M2极化。此外,通过系统注射IL-2/IL-2抗体复合体(IL-2/IL-2Ab),我们成功地诱导了中风后循环中Tregs的强劲增加,这是一种已建立的在体内扩大Tregs的方法。我们证明了IL-2/IL-2Ab诱导的Treg扩张减少了tMCAO后7d的髓鞘丢失,并改善了感觉运动功能。目前的建议将进一步探讨Treg在卒中后WM损伤和修复中的作用,并开发体内Treg扩展作为促进WM完整性和促进卒中后恢复的新策略。有待检验的中心假设是,Treg通过以IL-10依赖的方式将小胶质细胞/巨噬细胞极化为M2表型,促进中风后WM的完整性和长期恢复。本研究提出了三个具体目标:目的1.验证卒中后Treg治疗改善长期功能恢复和促进WM完整性的假设。目的2.验证这一假说,即Treg来源的IL-10使小胶质细胞/巨噬细胞极化向M2表型转变,从而促进卒中后WM的完整性。目的3.验证卒中后IL-2/IL-2Ab体内扩增Tregs能有效减轻卒中后长期WM损伤、促进神经功能恢复的假说。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Dandan Sun其他文献

Dandan Sun的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Dandan Sun', 18)}}的其他基金

BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10373039
  • 财政年份:
    2021
  • 资助金额:
    $ 33.69万
  • 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10231728
  • 财政年份:
    2021
  • 资助金额:
    $ 33.69万
  • 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10618190
  • 财政年份:
    2021
  • 资助金额:
    $ 33.69万
  • 项目类别:
Microglia in White Matter Repair after TBI
小胶质细胞在 TBI 后白质修复中的作用
  • 批准号:
    10044411
  • 财政年份:
    2020
  • 资助金额:
    $ 33.69万
  • 项目类别:
ShEEP Request for a High-Content Screening (HCS) Platform
ShEEP 请求建立高内涵筛选 (HCS) 平台
  • 批准号:
    10175276
  • 财政年份:
    2020
  • 资助金额:
    $ 33.69万
  • 项目类别:
Microglia in White Matter Repair after TBI
小胶质细胞在 TBI 后白质修复中的作用
  • 批准号:
    9778141
  • 财政年份:
    2020
  • 资助金额:
    $ 33.69万
  • 项目类别:
Microglia in White Matter Repair after TBI
小胶质细胞在 TBI 后白质修复中的作用
  • 批准号:
    10436769
  • 财政年份:
    2020
  • 资助金额:
    $ 33.69万
  • 项目类别:
Microglia in White Matter Repair after TBI
小胶质细胞在 TBI 后白质修复中的作用
  • 批准号:
    10553623
  • 财政年份:
    2020
  • 资助金额:
    $ 33.69万
  • 项目类别:
Long Non-Coding RNAs and Cerebral Angiogenesis in Ischemic Stroke
长非编码 RNA 与缺血性中风中的脑血管生成
  • 批准号:
    10605296
  • 财政年份:
    2020
  • 资助金额:
    $ 33.69万
  • 项目类别:
Regulatory T cell as a restorative therapy for ischemic stroke
调节性 T 细胞作为缺血性中风的恢复疗法
  • 批准号:
    10261318
  • 财政年份:
    2016
  • 资助金额:
    $ 33.69万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 33.69万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 33.69万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 33.69万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 33.69万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 33.69万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 33.69万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 33.69万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 33.69万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 33.69万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 33.69万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了